Journal of Alzheimers Disease & Parkinsonism
Open Access

Review Article

Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer's Related Pathological Changes in Down Syndrome

Boris DeCourt¹, William Mobley², Eric Reiman³, Raj Jatin Shah¹ and Marwan N Sabbagh^1*

¹Banner Sun Health Research Institute, Sun City AZ, USA

²University of California-San Diego, San Diego CA, USA

³Banner Alzheimer’s Institute, Phoenix AZ, USA

Corresponding Author:

Marwan N Sabbagh, MD
Banner Sun Health Research Institute
10515 West Santa Fe Drive
Sun City, AZ 85351, USA
Tel: (623) 832-6500
Fax: (623) 832-6504
E-mail: marwan.sabbagh@bannerhealth.com

Received date: January 27, 2013; Accepted date: March 12, 2013; Published date: March 20, 2013

Citation: DeCourt B, Mobley W, Reiman E, Shah RJ, Sabbagh MN (2013) Recent Perspectives on APP, Secretases, Endosomal Pathways and How they Influence Alzheimer’s Related Pathological Changes in Down Syndrome. J Alzheimers Dis Parkinsonism S7:002. doi:10.4172/2161- 0460.S7-002

Copyright: © 2013 DeCourt B, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Down syndrome is one of the most common genetic conditions occurring in one in 700 live births. The trisomy of chromosome 21 causes over-expression of APP which in turn is indicated in the increased production of Aβ associated with AD. This makes DS the most common presenile form of AD exceeding PS1 and PS2 FAD. Since a majority of DS individuals develop dementia, it is important to examine whether DS and sporadic AD share common features, for example, to anticipate shared treatments in the future. Here we explore commonalities and differences for secretases and endosomal pathways in DS and AD.

Keywords